Although the molecular mechanism involving GALNT9 and other factors in low-risk neuroblastoma patients remain largely unknown, the GALNT9 has been validated as a prognostic marker that may be helpful to guide therapy in low-risk neuroblastoma patients [77]. This evidence concerns the gene GALNT9 and neuroblastoma.